濱特爾股票討論區

You turn the DRIP on, and let compounding do its work. You do nothing for 10 years. Only exception is to reinvest money in all the aristocrats for any company that's acquired
You generate a decent return over time
$巴菲特持倉(BK2999.US)$$伯克希爾-A(BRK.A.US)$$伯克希爾-B(BRK.B.US)$$可口可樂(KO.US)$$信達思(CTAS.US)$$標普全球(SPGI.US)$$麥當勞(MCD.US)$$強生(JNJ.US)$$百事可樂(PEP.US)$$寶潔(PG.US)$$塔吉特(TGT.US)$$沃爾瑪(WMT.US)$$濱特爾(PNR.US)$$雪佛龍(CVX.US)$$美國史丹利公司(SWK.US)$$3M(MMM.US)$$威富集團(VFC.US)$

$濱特爾(PNR.US)$ initiated at buy by Deutsche Bank, announced target price at $75.00.
$Roku Inc(ROKU.US)$ initiated at neutral by Piper Sandler, announced targe price at $65.00.
$FREYR Battery(FREY.US)$ was upgraded by Morgan Stanley from equal-weight to overweight, increased target price to $13.00.
$美光科技(MU.US)$ was upgraded by Piper Sandler from underweight to neutral, increased target price from $45.00 to $70.00.
$輝瑞(PFE.US)$ was downg...

$濱特爾(PNR.US)$營收2018年大幅下滑40%，2020年開始連續恢復了3年，還沒恢復到2017年高點。營業利潤則在2021年達到高點，2022年小幅下滑6.5%，淨利潤2022年下滑13%。
利潤表顯示2022年成本費用均過量增長，造成營業利潤的下滑，5年來毛利率從35.3下滑到了33。
目前市盈率20，即使以2021年最高淨利潤5.5億計算，市盈率也達到了17，缺乏增長數據支持。

Moderna Upgraded to Buy From Hold at Jefferies
Jefferies analyst Michael Yee upgraded $Moderna(MRNA.US)$ to Buy from Hold with a price target of $275, up from $170. The shares can rebound in 2023 given the company's pipeline opportunities, Yee tells investors in a research note. He believes Moderna is the "new shiny thing" in personalized cancer vaccine following the recent positive Phase 2 data.
Atlantic Upgrades Warner Music on 'Solid...

Here are the top gap ups and downs for the stocks with a market cap above $5 billion after the previous market closed (gaps range from large to small):
Gap Ups
1. $Okta(OKTA.US)$ - up 14.96%
2. $Five Below(FIVE.US)$ - up 8.79%
3. $Splunk(SPLK.US)$ - up 8.74%
4. $英國保誠(PUK.US)$ - up 3.25%
5. $詹姆斯哈迪(JHX.US)$ - up 2.66%
6. $新思科技(SNPS.US)$ - up 2.49%
7. $帝亞吉歐(DEO.US)$ - up 1.62%
8. $費森尤斯醫療(FMS.US)$ - up 1.53...